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The diagnosis of cancer during pregnancy at least in the Western world is a rare phenomenon,
but this might be raised into the future due to late pregnancies in the modern societies. The
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Treatmentcoexistence of pregnancy and cancer implicates numerous medical, ethical, psychological and
sometimes religious issues between the mother, the family and the treating physician. Breast,
cervical cancer, melanoma and lymphoma are the most common malignancies diagnosed during
pregnancy. Diagnostic or therapeutic irradiation requires careful application, whereas systemic
chemotherapy is not allowed during the first trimester of pregnancy due to lethal or teratogenic
effects as well as to congenital malformations. In some gestational cancers, tumor cells can
invade the placenta or the fetus.
 2016 Production and hosting by Elsevier B.V. on behalf of Cairo University. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Sotirios Mitrou, MD, is a Senior obstetrician
and gynecologist, REA Maternal Hospital,
Athens, Greece.George Zarkavelis, MD, is a Fellow in Medi-
cal Oncology, Department of Medical
Oncology, Ioannina University Hospital,
Greece.George Fotopoulos, MD, is a Senior Oncolo-
gist, Department of Medicine, Sotiria Hospi-
tal, University of Athens, Greece.Dimitrios Petrakis, MD, PhD, is a Senior
Oncologist, Department of Medical Oncol-
ogy, Ioannina University Hospital, Greece.Nicholas Pavlidis, MD, PhD, FRCP Edin, is a
Professor and Head of the Department of
Medical Oncology, Ioannina University Hos-
pital, Greece. He is a member of Scientific
Committee and Coordinator of Master classes
of European School of Oncology and also a
member of Scientific Committee of ESMO/
ASCO Global Curriculum. He is the Editor in
Chief of Cancer Treatment Reviews.Introduction
Cancer during pregnancy represents a medical paradox in
humans and a dramatic event in a woman’s life, her partner
and her family. The management of gestational cancers is a
clinical dilemma since it involves two persons, the mother
and the fetus. Therefore, both diagnostic and therapeutic man-
agement should be individualized and should be undertaken by
a dedicated multidisciplinary team. It is of paramount impor-
tance that obstetricians and oncologists should offer at the
same time optimal treatment to mother and optimal protection
to the fetus.
Diagnosis of cancer during pregnancy in developed soci-
eties has an incidence of 1:1000 pregnancies ranging from
0.07% to 0.1%. The trend of this coexistence is becoming more
common over the last decades and it will probably be seen
more frequently, due to delaying pregnancy into the later
reproductive years. The most common gestational cancers
are those with a peak incidence during the woman’s reproduc-
tive period such as breast and cervical cancers, hematological
malignancies and melanoma (Table 1). However, most of the
gestational cancers have been described including gastroin-
testinal, renal or pulmonary malignancies [1–3].
Diagnostic and staging workup
With the increased use of radiation in diagnostic oncology,
concern for its biological effects continues to grow. Therefore,
rules and guidelines for the protection of people have been
Table 2 Imaging procedures and fetal radiation.
Imaging tests Fetal radiation dose (mGy)
Chest X-ray 0.001
Mammography <0.01
CT of the head <0.005
CT of the chest 0.06
Abdominal X-ray 1.4
99 mTc bone scintigraphy 3.3
CT of the abdomen 8.0
CT of the pelvis 9.4
Table 1 Incidence of cancers per pregnancies or deliveries.
Cancer type Incidence
Breast cancer 1:3.000–10.000
Cervical cancer 1:2.000–10.000
Hodgkin’s lymphoma 1:1.000–6.000
Melanoma 2–5:100.000
Leukemias 1:75.000–100.0000
Ovarian cancer 4–8:100.000
Colorectal cancer 1:13.000
Thyroid cancer 14:100.000
Courtesy by Voulgaris et al. [2].
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and X and gamma rays are the main types of radiation. Radi-
ation effects during pregnancy are depended on the gestational
age, dose, radiation field and fractionation.
Due to serum tumor marker production by both the tumor
and the pregnancy, the value of measuring them is limited i.e.
markedly elevated levels of CA125, CA15-3, and AFP [4].
From animal data, during the pre-implantation and
implantation period (0–2 weeks) irradiation with 100 mGy
(10 rads) results in embryonic death; however, during the
organogenesis period (3–12 weeks) additional developmental
malformations or teratogenesis can be seen. Exposure to irra-
diation during the second or third trimesters is associated with
growth or mental retardation, malformations of central ner-
vous system or gonads as well as premature death. With the
use of various imaging procedures the associated average uter-
ine/fetal doses range between 0.001 mGy for a chest X-ray and
25 mGy for an abdominal pelvic CT-scan Table 2 [5–10].
In summary, for radiological staging in pregnant mothers
with cancer, chest X-ray, abdominal ultrasound and mammog-
raphy are considered as safe procedures. In certain cases how-
ever, magnetic resonance imaging (MRI) can be recommended
(i.e. brain MRI) especially after the first trimester of preg-
nancy. Abdominal plain films, abdominal CT, radionuclide
isotope scans or PET/CT should be avoided.
Radiotherapy during pregnancy
Pregnant women with cancers removed from the pelvic field
(i.e. breast cancers and brain tumors) can be treated with
radiotherapy, always based on a very careful planning of fetal
dose and additional shielding. The proper treatment with
radiotherapy requires a very advanced multidisciplinary team.
In addition, special devices to shield the fetus are needed.Despite these measurements, several oncologists prefer to post-
pone radiotherapy after delivery in order to avoid scattered
radiation to the placenta or fetus [7].Systemic treatment during pregnancy
Systemic chemotherapy can be provided to pregnant mothers
with cancer under certain circumstances. Chemotherapy
administration during the first trimester of pregnancy increases
the risk of spontaneous abortion, fetal death, teratogenicity
and congenital malformations. Teratogenic effects have been
reported to be between 10% and 20%. However, chemother-
apy exposure during the second and third trimester, although
is followed by several fetal effects such as intrauterine growth
restriction, low-birth weight or myelosuppression, is generally
considered as safe.
In general, pregnancies are not allowed during cancer treat-
ment. If pregnancy occurs while the patient is under endocrine
treatment (i.e. tamoxifen) or chemotherapy a pregnancy termi-
nation should be recommended. Regarding monoclonal anti-
bodies trastuzumab administration is not allowed due to
mother’s and infant toxicity while rituximab is more safe. Sim-
ilarly, tyrosine kinase inhibitors in which no adequate data are
available administration during gestation is contraindicated
[1,11,12].
Antimetabolites
Antimetabolites especially methotrexate have the higher ter-
atogenic potential, while cytosine arabinoside is associated
with conflicting reports on the effects on fetal life.
Alkylating agents
Among the alkylating agents busulfan, chlorambucil and
dacarbazine have been reported to exhibit teratogenic effects.
Antibiotics
Anthracyclines are considered as safer cytotoxic during preg-
nancy especially when administered during the second or third
trimester. No early or late cardiotoxicity has been seen in
embryos, newborns, childhood or adolescence.
Vinca alkaloids
Vincas are considered to be the less potent teratogens or drug-
induced malformations.
Taxanes
The use of taxanes (parclitaxel or docetaxel) appears to be fea-
sible after the first trimester although less than 50 cases are
available in the literature.
Platinum compounds
These drugs are found to be safe during pregnancy, although
some cases of ototoxicity have been documented.
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Trastuzumab is associated with oligohydramnios or anhy-
dramnios, neonatal deaths, and transient respiratory or renal
failure. Rituximab can be administered with no congenital
anomalies. For imatinib, sunitinib, sorafenib or nilotinib, there
are no adequate data yet.
Hormonal treatment
Generally, it is not recommended during pregnancy.
Therapeutic management of the most common cancers during
pregnancy
Breast cancer
Pregnant women with breast cancer present with poor prog-
nostic factors and more advanced disease. Surgically, modified
radical mastectomy with axillary node dissection is recom-
mended for stage I–II and for selected stage III patients during
the first and second trimester. Breast conserving surgery fol-
lowing by breast irradiation is advised for patients with local-
ized disease during the third trimester or during postpartum.
Adjuvant chemotherapy can be administered with CMF or
anthracycline-based regiments. No hormonal or trastuzumab
treatments are indicated. Patients with metastatic breast cancer
should be directly treated with chemotherapy. Overall survival
is similar to the corresponding stage of non-pregnant women
with breast cancer. Termination of pregnancy may be consid-
ered when immediate therapy should be initiated especially
during the first trimester of gestation [1–3,13].
Cervical cancer
There is evidence that cervical cancer during pregnancy has a
3.1-fold higher chance of being diagnosed with early disease
(stage I) due to frequent gynecological examinations.
Cervical intraepithelial neoplasia (CIN) should be followed
up with cytology and colposcopy. Almost 80% of cases
regressed after delivery. For stage IA1 disease conization during
the second trimester is sufficient providing that surgical margins
are negative. Pregnancy termination with immediate treatment
might be advised for more advanced stages (IA1 with positive
margins, IA2, IIA or locally advanced disease) [1–3,14].
As an alternative, neoadjuvant chemotherapy can be rec-
ommended in patients who refuse pregnancy termination.
Overall survival is similar to non-pregnant women of the same
stage disease.
Melanoma
For localized disease, treatment of choice includes wide surgi-
cal excision (with 1–3 cm margins) and sentinel lymph node
biopsy. Adjuvant high-dose interferon has not been well stud-
ied. Pregnant patients with metastatic disease have a poor out-
come since no effective chemotherapy is advocated. In
addition, no data are available concerning targeted treatment
i.e. vemurafenib and ipilimumab. The choice of termination
of pregnancy should be discussed with the patient. Overallsurvival remains the same to non-pregnant women with mela-
noma [1–3,15].
Hodgkin’s lymphoma
If the diagnosis of Hodgkin’s lymphoma is made during the
first trimester a ‘‘watch and wait” approach is preferred until
the patient reaches the second trimester. Pregnant patients
with Hodgkin’s lymphoma after the first semester can be safety
managed with the gold standard chemotherapy of ABVD
(adriamycin, bleomycin, vinblastin, and dacarbazine) regimen.
Prognosis does not seem to be inferior to that of non-pregnant
patients [11,16].
Thyroid cancer
Pregnant mothers with well differentiated carcinomas (follicu-
lar or papillary) can be candidates for delayed surgical man-
agement. Radioactive iodine is a contraindication in breast
feeding women, while patients on levothyroxine should be
carefully monitored [17].
Monitoring of pregnancy and mode of delivery
Pregnancy in women with cancer should be considered as a
high risk situation especially when chemotherapy is initiated.
Therefore, regular fetal monitoring is highly recommended as
well as continued follow-up of newborns until puberty. In
addition, therapeutic drug monitoring for appropriate drug
disposition due to pregnancy changes is essential [18,19].
In general, a normal vaginal delivery in the absence of
maternal or neonatal complications is recommended apart
from cervical and vulvar cancers, although the mode of deliv-
ery is determined by the obstetricians [20].
Metastases to the product of conception
Metastatic transmission to placenta or fetus mostly occurs
through the hematogenous route, whereas lymphatic dissemi-
nation or contiguous invasion is less common metastatic path-
way. The real incidence is lacking, since routine histological
and cytological examination of the placenta and of the umbil-
ical cord are not usually performed and most newborns are
missing a close follow-up.
Metastatic lesions to placenta or fetus are most frequently
observed in melanoma (30%), cancer of unknown primary
(22.5%), leukemias and lymphomas (15%), breast cancer
(14%), and lung cancer (13%).
In these cases, histological examination of the placenta
revealed tumor cell sequestration in the intervillous spaces.
Fetal metastases always preceded by infiltration of the chori-
onic villous by tumor cells. The clinical manifestations of new-
born metastases were mainly located on the skin (scalp) or
internal organs. In some infants metastases exhibited sponta-
neous resolution [21–23].
Pregnancy in cancer survivors
It has recently been shown that pregnancy rates found to be
40% lower among women cancer survivors compared with
Pregnant mothers with cancer 563the general population but this depends on the tumor type.
Mothers diagnosed with thyroid cancer or melanoma had
pregnancy rates highly compared with the general population.
However, females with breast cancer had the lowest pregnancy
rates close to 70% lower, compared to the general population
probably due to previous chemotherapy or endocrine
treatment.
The optimal timing to allow patients to become pregnant
cannot be easily predicted since it depends on the time of com-
pletion of treatment and the risk of relapse. For breast cancer
patients postpone of pregnancy for two years is recommended
[24].
Conclusions
In conclusion, the coexistence of cancer and pregnancy is rare
phenomenon with the most common tumors diagnosed are
breast, cervical cancer, melanoma and hematological malig-
nancies. Chemotherapy can be used with safety after the first
trimester of pregnancy. In difficult cases mainly during the first
trimester, the final decision should be taken after thorough dis-
cussion between the mother, the father and the treating physi-
cian. All obstetricians should be aware that cancer in pregnant
women could rarely invade the products of conceptions.
Therefore, meticulous examination of the placenta and the
umbilical cord is necessary.Conflict of interest
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